Articles On Orthocell (ASX:OCC)
Title | Source | Codes | Date |
---|---|---|---|
Beyond Resources Part 2: ASX companies driving WA’s medical and life sciences sector
Western Australia wanting to diversity beyond resources and become a global leader in health and medical life sciences Cook Government to invest $16m into driving a connected and innovative ecosystem for WA’s health and medical research se... |
Stockhead | OCC | 1 week ago |
National biotech summit shows off a wealth of healthcare and medical innovation
The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improve... |
Stockhead | OCC | 2 weeks ago |
Orthocell to start selling dental bone repair product Striate in Canada following regulatory approval
Shares in WA regenerative medicine company Orthocell are up after it received regulatory approval to start selling its dental bone repair product in Canada. |
The West | OCC | 2 weeks ago |
ASX Market Close: ASX posts strong gain of 0.93% | 11 July 2024
The ASX200 had a strong day closing up 0.93%. All sectors closed in the green with top performer Real Estate jumping 1.5%, followed closely by IT and Healthcare. In this bulletin, we’ll discuss Renascor, Telix Pharmaceuticals, Orthoc... |
themarketonline.com.au | OCC | 2 weeks ago |
Closing Bell: This ASX looks ready to cut its own records after latest Wall Street highs
ASX 200 punches it, record highs back in view 11 of 11 sectors higher, like a well-oiled machine Great day for small caps, goldies and Augustus Minerals Local markets surged this morning after yet another record-breaking night for Wa... |
Stockhead | OCC | 2 weeks ago |
Orthocell to sell Striate in Canada after regulatory approval
Orthocell receives regulatory approval to sell dental guided bone regeneration product Striate+ in Canada Approval complements existing approvals for Striate+ in other key markets including the US Orthocell’s distribution partner Bio Hor... |
Stockhead | OCC | 2 weeks ago |
Closing Bell: ASX ends almost okay after Telstra-led recovery
ASX 200 closes 0.16pc lower after modest rally from morning lows Six of 11 sectors lower, after rate-sensitive sectors improve after lunch Killi Resources surges again with a late surge to dethrone Infini Local markets have trimmed... |
Stockhead | OCC | 2 weeks ago |
Closing Bell: The benchmark strikes back as Telstra leads broad based gains
ASX 200 rises strongly on Tuesday, closes up +0.86pc All 11 sectors in the green, like Kermit on a golf course Top small cap was Killi Resources with a bumper +83.7pc surge Local markets jumped on Tuesday, erasing all of Monday’s l... |
Stockhead | OCC | 2 weeks ago |
Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
Special Report: Dropping milestone numbers this week is the Perth-based regenerative medtech Orthocell, for which record quarterly and full year revenue has been driven by a huge uptick in demand across the company’s flagship healing solu... |
Stockhead | OCC | 2 weeks ago |
Orthocell shares jump on record revenues from sales of collagen bone repair devices globally
Orthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged record yearly revenues. The company sells two keystone products – Striate+ and Remplir respectively – both aimed at regenerating bones and... |
themarketonline.com.au | OCC | 2 weeks ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | OCC | 3 weeks ago |
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin PERTH, Australia, July 2, 2024 /PRNewswire/ — Bridgewest Perth Pharma, global pha... |
FNArena | OCC | 3 weeks ago |
Closing Bell: ASX buried under -1.3pc as iron ore miners and goldies take a beating
Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes Aussie shares slipped after the K... |
Stockhead | OCC | 1 month ago |
ASX Health Stocks: Orthocell seeks TGA approval; Race Oncology gets FDA nod
Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to... |
Stockhead | OCC | 1 month ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | OCC | 1 month ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | OCC | 2 months ago |
Regenerative med firm Orthocell reports near 100pc success rate for dental bone repair product Striate
WA regenerative medicine company Orthocell has reported a near 100 per cent success rate for its dental bone repair product during a recent clinical study. |
The West | OCC | 2 months ago |
ASX Health Stocks: RAC says combining lead drug bisantrene with decitabine is effective on solid tumours
Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race... |
Stockhead | OCC | 2 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | OCC | 2 months ago |
Market Close: Quarter gained on sluggish ASX
The ASX200 closed around a quarter of a per cent up with Consumer discretionary topping the gains, finishing nearly half a per cent up and Utilities and Industrials both losing around half a per cent. In the green Mineral explorer IGO... |
themarketonline.com.au | OCC | 2 months ago |
Orthocell’s Remplir shows 85% success rate in nerve repair study
Regenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Remplir nerve regeneration clinical trial, unveiling promising progress in its peripheral nerve repair journey – offering hope for millions of peo... |
themarketonline.com.au | OCC | 2 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | OCC | 3 months ago |
Botanix joins ASX All Ordinaries as fellow biotech Orthocell boosts cash reserves with $3m R&D tax rebate
Perth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up of the top 500 companies listed on the Australian Securities Exchange. |
The West | OCC | 3 months ago |
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. |
BiotechDispatch | OCC | 4 months ago |
Biotech Orthocell on track to further penetrate US market with Remplir following ‘successful’ study
Regenerative medicine company Orthocell says it has successfully completed the first stage of a pivotal US market authorisation study for its nerve repair product, paving the way for global expansion. |
The West | OCC | 4 months ago |
ASX Health Stocks: Argenica flies over 15pc after FDA grants Rare Pediatric Disease Designation
Argenica granted US FDA’s Rare Pediatric Disease Designation Orthocell completes Remplir study, targets US$1b+ nerve repair device market LTR Pharma progresses Erectile Dysfunction study Argenica gets FDA approval Argenica Therapeutics... |
Stockhead | OCC | 4 months ago |
Brokers meet Biotech – four Aussie companies driving medtech solutions
Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and... |
themarketonline.com.au | OCC | 4 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | OCC | 4 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | OCC | 4 months ago |
Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
The $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and Tonya McCusker and Michael Malone, along with the Merchant Biotech Fund. |
The West | OCC | 5 months ago |
Closing Bell: Aussie benchmark fails Tuesday pub test. We should all be there now
Local markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat The ASX200 has ended a second slumbrous session slightly lower, with a little dribble in the shape of the Star Casino at the corner of its mouth. US M... |
Stockhead | OCC | 5 months ago |
Orthocell announces final positive results of cell therapy in 'tennis elbow' study
Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis. |
BiotechDispatch | OCC | 8 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | OCC | 8 months ago |
Dr Boreham’s Crucible: Investors have been holding their breath for Pharmaxis’ rebirth. Time to exhale?
In drug development there’s a narrow window to get to market and long delays tend to be fatal – and not just for the patients. Ten years ago, Pharmaxis was confident of US Food and Drug Administration approval for its cystic fibrosis treatm... |
Stockhead | OCC | 8 months ago |
Famed plastic surgeon Fiona Wood joins WA biotech Orthocell as a non-executive director
Perth-based regenerative medicine company Orthocell has appointed famed plastic surgeon Fiona Wood to its board as a non-executive director. |
The West | OCC | 9 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | OCC | 9 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | OCC | 9 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | OCC | 10 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | OCC | 10 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | OCC | 10 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | OCC | 11 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | OCC | 11 months ago |
Orthocell’s product sales ‘significantly’ higher than expected
Orthocell’s sales ramped up in three months to June with the Perth-based regenerative medicine company described as testament to the quality of its products and distribution partners. |
The West | OCC | 11 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | OCC | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | OCC | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | OCC | 1 year ago |
Orthocell taps former health sector leader to chair its board of directors
Australian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wielen as independent non-executive chairman. |
BiotechDispatch | OCC | 1 year ago |
Orthocell all smiles with dental biotech manufacturing site at Murdoch
Orthocell has launched a new bio-manufacturing facility in what boss Paul Anderson said represented the successful translation of quality science into a world-class product. |
The West | OCC | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | OCC | 1 year ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | OCC | 1 year ago |